Zenith Drugs Ltd
Pharmaceuticals & Biotechnology | Small Cap
Zenith Drugs Ltd demonstrates a mixed financial performance. The company shows strength in solvency and profitability. However, liquidity, efficiency, and growth metrics are concerning. The company has low debt levels, indicating financial stability and reduced risk. Profitability ratios such as ROCE, ROE, and margins are strong, suggesting efficient operations and good earnings generation. Poor liquidity indicates potential difficulties in meeting short-term obligations. Inefficiency in asset utilization and a significant drop in revenue, operating profit, EPS, assets, and net income indicate the company is facing serious challenges. There is a moderate ability to cover interest and dividends. The company has poor EPS and book value per share, but manages capital expenditures reasonably well.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.00
- Financial Ratio4.20
- Profitability Ratio9.60
- Efficiency Ratio3.33
- Coverage Ratio6.00
- Solvency Ratio9.00
- Liquidity Ratio2.68
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBearish
- 1 WeekNeutral
- 1 MonthNeutral
Zenith Drugs Ltd demonstrates a mixed financial performance. The company shows strength in solvency and profitability. However, liquidity, efficiency, and growth metrics are concerning. The company has low debt levels, indicating financial stability and reduced risk. Profitability ratios such as ROCE, ROE, and margins are strong, suggesting efficient operations and good earnings generation. Poor liquidity indicates potential difficulties in meeting short-term obligations. Inefficiency in asset utilization and a significant drop in revenue, operating profit, EPS, assets, and net income indicate the company is facing serious challenges. There is a moderate ability to cover interest and dividends. The company has poor EPS and book value per share, but manages capital expenditures reasonably well.
Overall Valuation Score
P/E RATIO (TTM)
18.28
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
7.52
P/B RATIO
1.16
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
0.52
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
3.98
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹42.05 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth ratios are negative, indicating significant challenges. Declines in revenue, operating profit, EPS, assets, and net income suggest business contraction. This could reflect market challenges or internal operational issues. The negative growth rates raise concerns about the company's future prospects and sustainability. Focus needs to be on identifying the root causes of decline and implementing corrective strategies.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Revenue Growth Rate | 23.91 | 14.91 | |
| Operating Profit Growth Rate | 28.57 | 88.89 | |
| Earnings Per Share (EPS) Growth | |||
| Asset Growth Rate | 42.03 | 37.76 | |
| Net Income Growth Rate | 66.67 | 100 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed view. While capital expenditures are managed reasonably well, the adjusted and cash EPS are low. The book value and dividend per share are also poor. The company needs to improve its earnings and shareholder value.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 75 | 125 | 6.47 |
| Cash Earnings Per Share (Cash EPS) | 100 | 150 | 6.47 |
| Book Value Per Share | 310 | 435 | 36.47 |
| Dividend Per Share (DPS) | 0.5 | ||
| Capital Expenditures (CapEx) | 2.6 | 5.6 | 5.3 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are strong. High gross profit, ROCE, ROE, operating margin, and net margin indicate efficiency in operations and good earnings generation. The return on assets is reasonably good. The company is generating profits from its assets and equity.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Gross Profit Margin | 6.52 | 7.02 | 12.21 |
| Return on Capital Employed (ROCE) | 27.3 | 24 | 27 |
| Return on Equity (ROE) | 24.19 | 28.74 | 16.13 |
| Return on Assets (ROA) | 10.14 | 9.18 | 12.59 |
| Operating Margin | 7.61 | 7.89 | 12.98 |
| Net Margin | 3.26 | 4.39 | 7.63 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While the days sales in inventory is relatively reasonable, indicating effective inventory management, the fixed asset, inventory, and capital turnover ratios are low, suggesting inefficient asset utilization. The high receivable days indicate challenges in collecting payments. There is potential for improvement in converting assets into revenue and managing receivables.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Fixed Asset Turnover Ratio | 9.2 | 9.5 | 11.91 |
| Inventory Turnover Ratio | 7.17 | 5.83 | 4.6 |
| Receivables Turnover Ratio | 2.85 | 2.81 | 2.26 |
| Days Sales in Inventory Ratio | 50.91 | 62.61 | 79.35 |
| Receivable Days | 128 | 129.89 | 161.5 |
| Capital Turnover Ratio | 4.19 | 4.43 | 1.86 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios show a moderate ability to meet its interest and dividend obligations. The interest coverage ratio indicates that the company can cover its interest expenses. The equity dividend coverage ratio suggests an ability to cover dividend payments. The company is meeting its obligations.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Interest Coverage Ratio | 3 | 4.5 | 5.33 |
| Equity Dividend Coverage Ratio | 11.11 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency. Low debt and debt-to-equity ratios suggest minimal financial risk and a strong equity base. A high equity ratio further confirms financial stability. This allows the company greater flexibility in funding future growth and weathering economic downturns. The company's asset base is not overly burdened by debt, contributing to long-term sustainability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Debt Ratio | 0.44 | 0.32 | 0.12 |
| Debt to Equity Ratio | 0.79 | 0.47 | 0.14 |
| Equity Ratio | 0.56 | 0.68 | 0.88 |
| Debt To Asset Ratio | 0.14 | 0.09 | 0.06 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position raises concerns. The current and cash ratios are particularly weak, indicating a struggle to meet short-term obligations using liquid assets. While the quick ratio offers a slightly better outlook, the negative operating cash flow ratio suggests operational inefficiencies. Limited liquid assets may restrict flexibility in handling unforeseen expenses or investment opportunities.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Current Ratio | 1.16 | 1.2 | 1.87 |
| Quick Ratio | 0.91 | 0.86 | 1.47 |
| Cash Ratio | 0.06 | 0 | 0.14 |
| Operating Cash Flow Ratio | 0.11 | -0.07 | -0.2 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 8.88 | Undervalued | 17.00 | 10.65 | 13.00 |
| 2 | Vaishali Pharma Ltd | 6.74 | 103.62 | Overvalued | 4.00 | 0.31 | 4.00 |
| 3 | Mono Pharmacare Ltd | 6.16 | 6.26 | Neutral | 8.00 | 1.75 | 3.00 |
| 4 | JFL Life Sciences Ltd | 6.07 | 9.43 | Neutral | 12.00 | 1.94 | 6.00 |
| 5 | Quest Laboratories Ltd | 5.27 | 11.21 | Neutral | 18.00 | 9.16 | 15.00 |
| 6 | Sotac Pharmaceuticals Ltd | 5.27 | 21.26 | Neutral | 18.00 | 4.45 | 6.00 |
| 7 | Zenith Drugs Ltd | 4.63 | 7.52 | Neutral | 17.00 | 2.30 | 10.00 |
| 8 | Mangalam Drugs and Organics Ltd | 4.50 | -1.07 | Neutral | -15.00 | -27.68 | -44.00 |
| 9 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 10 | Krebs Biochemicals & Industries Ltd | 4.16 | -5.27 | Highly Undervalued | -4.00 | -12.49 | -4.00 |
Zenith Drugs' management shows promise with strong sales and profit growth, alongside improvements in operational efficiency. The company benefits from a substantial promoter holding. However, there are areas of concern, particularly regarding working capital management. Increasing debtor and inventory days, coupled with a shift in the cash conversion cycle, indicate operational inefficiencies. These factors suggest a mixed performance, where strengths in profitability are counterbalanced by challenges in managing working capital effectively.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Profit Growth | TTM: 115% | Showing very strong growth |
| OPM Improvement | Mar 2022: 8% to Mar 2024: 13% | Demonstrating improving operational efficiency | |
| Promoter Holding | 69.98% | Indicating confidence and alignment with shareholders | |
| CONS | Increasing Debtor Days | Mar 2022: 128 to Mar 2024: 188 | Suggesting potential issues with credit management |
| Increasing Inventory Days | Mar 2022: 96 to Mar 2024: 249 | Indicating potential challenges in inventory turnover |
Financial Performance & Growth
Zenith Drugs has demonstrated notable financial performance with improvements in sales and profitability. The compounded sales growth shows a positive trend with TTM growth at 15%. The compounded profit growth is significant, with TTM at 115%. The Operating Profit Margin (OPM) has improved from 8% in Mar 2022 to 13% in Mar 2024, reflecting enhanced operational efficiency. Expenses also increased from 85 in Mar 2022 to 114 in Mar 2024.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Sales Growth (%) | 23.88% | 15.44% | |
| OPM (%) | 8% | 8% | 13% |
Capital Efficiency & Returns
Zenith Drugs exhibits strong capital efficiency and returns, with a Return on Capital Employed (ROCE) and Return on Equity (ROE). The ROCE has improved to 27% in Mar 2024. The Return on Equity (ROE) stands at 26% in the last year.
| Metric | Mar 2023 | Mar 2024 |
|---|---|---|
| ROCE (%) | 24% | 27% |
Financial Health & Prudence
Zenith Drugs' borrowings have remained relatively stable, with borrowings at 25 in Mar 2024. The dividend payout stands at 9% in Mar 2024.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Borrowings | 19 | 26 | 25 |
| Dividend Payout (%) | 0% | 0% | 9% |
Strategic & Operational Indicators
Zenith Drugs faces challenges in its working capital management. Debtor days have increased from 128 in Mar 2022 to 188 in Mar 2024. Inventory days have risen from 96 in Mar 2022 to 249 in Mar 2024. The Cash Conversion Cycle has shifted from -50 in Mar 2022 to 25 in Mar 2024.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Debtor Days | 128 | 159 | 188 |
| Inventory Days | 96 | 192 | 249 |
| Cash Conversion Cycle | -50 | -62 | 25 |
The risk assessment for Zenith Drugs indicates a moderate level of risk. Strengths in profitability and returns are present, but concerns exist regarding working capital management. The increasing debtor days and inventory days suggest potential liquidity issues and operational inefficiencies.
Off-balance sheet exposure quantification
The increasing 'Other Liabilities' from 38 in Mar 2022 to 48 in Mar 2024 could potentially include some off-balance sheet obligations.
Contingent liability evaluation
The data provided does not offer specific details on contingent liabilities.
Accounting quality red flags
Based on the available data, there are no significant accounting quality red flags for Zenith Drugs.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1041.63Bullish
- SMA 2041.48Bullish
- SMA 5042.16Bullish
- EMA 1041.60Bullish
- EMA 2041.74Bullish
- EMA 5042.00Bullish
- DEMA 1041.51Bullish
- DEMA 2041.48Bullish
- DEMA 5041.79Bullish
- TEMA 1041.60Bullish
- TEMA 2041.42Bullish
- TEMA 5041.50Bullish
- MACD-0.19Bullish
- ADX14.45Weak Trend
- IndicatorValueSignal
- RSI54.74Neutral
- CCI65.07Neutral
- ROC 90.83Bullish
- ROC 144.94Bullish
- ROC 25-3.19Bearish
- Stoch K40.51Neutral
- Stoch D23.68Neutral
- IndicatorValueSignal
- BB Upper43.23Neutral
- BB Middle41.48Neutral
- BB Lower39.73Neutral
- ATR0.59High Volatility
- IndicatorValueSignal
- MFI50.55Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1041.70Bullish
- SMA 2042.13Bullish
- SMA 5042.10Bullish
- EMA 1041.84Bullish
- EMA 2041.95Bullish
- EMA 5042.05Bullish
- DEMA 1041.77Bullish
- DEMA 2041.76Bullish
- DEMA 5042.12Bullish
- TEMA 1041.85Bullish
- TEMA 2041.69Bullish
- TEMA 5041.90Bullish
- MACD-0.14Bullish
- ADX15.12Weak Trend
- IndicatorValueSignal
- RSI52.26Neutral
- CCI2.63Neutral
- ROC 94.94Bullish
- ROC 14-0.58Bearish
- ROC 25-1.05Bearish
- Stoch K38.62Neutral
- Stoch D33.97Neutral
- IndicatorValueSignal
- BB Upper44.48Neutral
- BB Middle42.13Neutral
- BB Lower39.78Neutral
- ATR0.91High Volatility
- IndicatorValueSignal
- MFI41.86Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1042.23Bullish
- SMA 2042.16Bullish
- SMA 5041.71Bullish
- EMA 1042.06Bullish
- EMA 2042.17Bullish
- EMA 5041.97Bullish
- DEMA 1041.87Bullish
- DEMA 2042.12Bullish
- DEMA 5042.37Bullish
- TEMA 1041.82Bullish
- TEMA 2041.87Bullish
- TEMA 50N/AN/A
- MACD-0.07Bearish
- ADX12.38Weak Trend
- IndicatorValueSignal
- RSI51.00Neutral
- CCI-16.42Neutral
- ROC 9-3.19Bearish
- ROC 142.91Bullish
- ROC 25-4.39Bearish
- Stoch K38.96Neutral
- Stoch D49.21Neutral
- IndicatorValueSignal
- BB Upper44.41Neutral
- BB Middle42.16Neutral
- BB Lower39.90Neutral
- ATR1.65High Volatility
- IndicatorValueSignal
- MFI61.33Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1042.38Bearish
- SMA 2042.53Bearish
- SMA 5042.03Bullish
- SMA 10043.75Bearish
- SMA 20051.50Bearish
- EMA 1042.15Bearish
- EMA 2042.11Bearish
- EMA 5042.39Bearish
- EMA 10044.72Bearish
- EMA 20050.87Bearish
- DEMA 1042.08Bearish
- DEMA 2042.25Bearish
- DEMA 5041.04Bullish
- DEMA 10038.89Bullish
- DEMA 20038.90Bullish
- TEMA 1041.90Bullish
- TEMA 2042.32Bearish
- TEMA 5042.34Bearish
- TEMA 10040.28Bullish
- TEMA 200N/AN/A
- MACD0.08Bearish
- ADX11.61Weak Trend
- IndicatorValueSignal
- RSI49.92Neutral
- CCI-32.81Neutral
- ROC 14-3.56Bearish
- ROC 252.56Bullish
- Stoch K45.97Neutral
- Stoch D37.31Neutral
- IndicatorValueSignal
- BB Upper46.82Neutral
- BB Middle42.53Neutral
- BB Lower38.23Neutral
- ATR2.35Low Volatility
- IndicatorValueSignal
- MFI48.42Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2043.51Bullish
- SMA 5054.45Bearish
- EMA 2044.63Bearish
- EMA 5053.11Bearish
- DEMA 2039.59Bullish
- DEMA 5039.89Bullish
- TEMA 2041.10Bullish
- TEMA 50N/AN/A
- MACD-3.41Bullish
- ADX14.96Weak Trend
- IndicatorValueSignal
- RSI44.13Neutral
- CCI-80.35Neutral
- ROC 14-2.88Bearish
- ROC 25-13.58Bearish
- Stoch K64.05Neutral
- Stoch D55.14Neutral
- IndicatorValueSignal
- BB Upper50.73Neutral
- BB Middle43.51Neutral
- BB Lower36.28Neutral
- ATR5.92Low Volatility
- IndicatorValueSignal
- MFI35.86Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 646.27Bullish
- SMA 1255.91Bearish
- SMA 2471.62Bearish
- EMA 647.51Bullish
- EMA 1254.54Bearish
- EMA 2466.95Bearish
- DEMA 641.54Bullish
- DEMA 1242.26Bullish
- DEMA 24N/AN/A
- TEMA 642.54Bullish
- TEMA 12N/AN/A
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX8.51Weak Trend
- IndicatorValueSignal
- RSIN/AN/A
- CCIN/AN/A
- ROC 25-25.20Bearish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper99.67Neutral
- BB Middle66.10Neutral
- BB Lower32.53Neutral
- ATR18.70Low Volatility
- IndicatorValueSignal
- MFI42.96Neutral